LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

Начало・Списък с акции・Schrodinger Inc

Schrodinger Inc

Отворен

СекторЗдравеопазване

12.47 3.49

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.86

Максимум

12.5

Ключови измерители
By Trading Economics
Приходи	-196M -60M
Продажби	-29M 59M
EPS	-0.621
Марж на печалбата	-102.456
Служители	850
EBITDA	-85M -49M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+56.8% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-64M 900M
Предишно отваряне	8.98
Предишно затваряне	12.47

Настроения в новините

By Acuity

72%

28%

316 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

23.27 / 26.13 Подкрепа & съпротива

Schrodinger Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.05.2026 г., 23:31 ч. UTC

Горещи акции

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20.05.2026 г., 22:52 ч. UTC

Значими двигатели на пазара

Osisko Shares Fall on Planned Convertible Notes Offering

20.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20.05.2026 г., 23:44 ч. UTC

Печалби

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20.05.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20.05.2026 г., 23:30 ч. UTC

Пазарно говорене

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20.05.2026 г., 23:15 ч. UTC

Пазарно говорене

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20.05.2026 г., 23:14 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20.05.2026 г., 23:02 ч. UTC

Пазарно говорене

KMD Brands Faces Two Testing Hurdles -- Market Talk

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.05.2026 г., 22:51 ч. UTC

Пазарно говорене

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20.05.2026 г., 22:51 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.05.2026 г., 22:27 ч. UTC

Пазарно говорене

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20.05.2026 г., 22:14 ч. UTC

Пазарно говорене

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20.05.2026 г., 22:10 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20.05.2026 г., 22:00 ч. UTC

Печалби

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20.05.2026 г., 21:38 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20.05.2026 г., 21:27 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20.05.2026 г., 21:20 ч. UTC

Печалби

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20.05.2026 г., 21:19 ч. UTC

Печалби

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20.05.2026 г., 21:18 ч. UTC

Печалби

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20.05.2026 г., 21:16 ч. UTC

Печалби

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Schrodinger Inc Прогноза

Ценова цел

By TipRanks

56.8% нагоре

12-месечна прогноза

Среден 18.8 USD 56.8%

Висок 24 USD

Нисък 13 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Schrodinger Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Schrodinger Inc през последните 3 месеца.

Техническа оценка

By Trading Central

23.27 / 26.13Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

316 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.